Daniel Vasella, M.D.


Served as Chairman of Novartis AG, a leading global medicines company, from 1999 until 2013 and as Chief Executive Officer of Novartis AG from 1996 to January 2010. From 1992 to 1996, Dr. Vasella held the positions of Chief Executive Officer, Chief Operating Officer, Senior Vice President and Head of Worldwide Development and Head of Corporate Marketing at Sandoz Pharma Ltd. He also served at Sandoz Pharmaceuticals Corporation from 1988 to 1992. Dr. Vasella is currently working as strategic advisor and coach to senior executives. He is also a director of PepsiCo and American Express Company, and is a member of several non-profit organizations.

Board of Directors

Markus Hosang, PhD


Markus Hosang is a General Partner of BioMedPartners AG, Basel Switzerland.  Beforehand, Dr. Hosang was Venture Partner at MPM Capital, where he was co-responsible for the European deal flow, managed the European office in Munich, and served on the board of several portfolio companies. Prior to joining MPM in 2002, Dr Hosang served for nearly 20 years at Hoffmann-La Roche in several senior management positions in the Global Pharma R&D organization, including VP and Director of the International Pharma Research Strategy Unit and Chief of Staff to the President of Roche Global R&D. He served on the Global Board of R&D Directors and the Pharma Portfolio Board. In his last position at Roche, he was VP and CSO of Genetics and Integrated Medicine and a member of the Roche Genetics Executive Committee. He also the Chairman of the Board of Directors of Unitectra AG, the joint tech transfer office of the Universities of Zurich, Bern and Basel.

Dr Hosang received his Ph.D. degree in Biochemistry from the ETH in Zurich and pursued postgraduate fellowships at Stanford University Medical School, and at the University of Washington Medical School in Seattle.

Michael Baran, MBA, PhD


Executive Director, WRD and Principal at Pfizer Ventures. Mike is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer’s investments in Imcheck Therapeutics, ImmunOs Therapeutics, Accelerator NYC, AnTolRx, and Biodesy.

Prior to his current role, Mike served as Senior Director of Portfolio Strategy and was responsible for critically assessing the R&D portfolio from a volume, value, quality, risk and productivity perspective with the ultimate objective of maximizing R&D productivity and value generation.  Prior to that, Mike was Senior Director, Scientific Affairs for the R&D President’s Office where he was responsible for enabling and communicating the R&D strategic agenda as well as leading colleague development capabilities. Mike joined Pfizer in 2008 in the market access space providing strategic and analytical support around marketing and managed care contracting with commercial and government payers. 

Prior to 2008, Mike worked within the NIH Protein Structure Initiative’s Northeast Structural Genomics Consortium coordinating protein structure production efforts, including bioinformatics, protein expression/purification and 3D structure determination.  Mike is also a co-founder of Nexomics Biosciences, a NJ based biotechnology company focused on providing gene-2-structure services as well as early stage drug target validation.  He is actively involved in the local biotechnology community participating in eLabNYC, BioIdea, and Rutgers Tech Advance – all organizations aiming to connect entrepreneurs from the NY/NJ area with local scientific and business leaders.

Mike earned his Ph.D. from Robert Wood Johnson Medical School / Rutgers, the State University of New Jersey in biochemistry where his research focused on structural biology and scientific software development. He holds a M.B.A. from Rutgers Business School with a focus in pharmaceutical management and received his B.S. in Biochemistry / Information Technology from Syracuse University.​

Reinhard Ambros, PhD


In his career Dr. Reinhard Ambros has gained broad experience in international leadership positions in venture capital, corporate strategy, BD&L and pharmaceutical product development. He serves on the board of public and private bio-technology companies in Europe and the US. He also serves as advisor to German and Swiss Government Biotechnology Funds. From 2005 to 2017, Dr. Ambros developed the Novartis Venture Fund to one of the largest and most active corporate biotechnology venture funds in the life sciences industry. In positions before he served as head of group strategic planning and BD&L for cardiovascular and metabolic diseases for Novartis Corporation and Novartis Pharma AG respectively.

Dr. Ambros received an M.S. in pharmacy and a Ph.D. in medicinal chemistry and pharmacology from the University of Regensburg, Germany.

Sean R. Smith


Mr. Smith has served as CEO and a member of the Board of Directors for ImmunOs Therapeutics AG since May of 2017.  Mr. Smith previously spent over 15 years at MSD/Merck and Co., Inc in positions of increasing responsibility in commercial leadership, cross-departmental management, business development, country, and regional operations with broad exposure to multiple therapeutic areas including early-stage clinical, in-line, and launch portfolios in Hospital/Specialty, Infectious Disease, General Medicine, and Vaccines. He has extensive leadership experience in global markets focused in North America, Europe, Asia-Pacific, China, Japan, and Latin America. Mr. Smith received his B.S. from Pennsylvania State University and M.B.A. from the University of Denver​